Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Business Wire•02/11/2026•06:45 ET
0
Key Highlights
- ➤FDA accepts two supplemental IDVYNSO applications; PDUFA target date April 22, 2027
- ➤Merck will present Week 48 ISL/LEN Phase 3 subgroup safety and efficacy analyses
- ➤Adult enrollment complete in both Phase 3 alimatravir once-monthly PrEP trials
- ➤Merck will present Week 96 IDVYNSO patient-reported outcomes at HIV Glasgow
- ➤Week 24 ISL/ULO data informed updated ulonivirine population pharmacokinetic model
Expert Statements
Luisa Stamm, Associate vice president and HIV section head at Merck Research Laboratories
“The data being presented at HIV Glasgow reflect the breadth of our research across HIV treatment and prevention. Our goal is to bring forward oral options, including daily and once-weekly HIV treatment regimens, as well as a once-monthly HIV prevention pill. Because no single medicine works for every person, we are committed to expanding choices that may help address the diverse needs and preferences of people living with HIV or those who could benefit from PrEP.”
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxis
Get started
Create a free account to read the full story.